Press releases
-
25 April 2013 - Paris (France)Ipsen expects Increlex® supply interruption due to supplier manufacturing issues
-
25 April 2013 - Paris (France)Active Biotech and Ipsen update the analysis plan for the 10TASQ10 trial evaluating tasquinimod in the treatment of prostate cancer
-
25 April 2013 - Paris (France)Ipsen’s first quarter 2013 sales
-
24 April 2013 - Paris (France)Combined Shareholders’ Meeting of Ipsen on 31 May 2013: Proposals of renewal of the terms of office of two Directors and appoint
-
23 April 2013 - Paris (France)The 21 st Colloque Médecine et Recherche of the Fondation Ipsen in the Neurosciences series: “New frontiers in social neuroscience”
-
10 April 2013 - Tokyo (Japan), Paris (France)PeptiDream and Ipsen enter into a collaboration for advancing drug discovery efforts for peptides to treat serious disease
-
9 April 2013 - Paris (France) and Montreal (Canada)Ipsen’s Dysport® approved for use in aesthetic medicine in Canada to be marketed by Medicis Aesthetics Canada
-
27 March 2013 - Paris (France)The Ipsen Group publishes its 2012 Registration document
-
21 March 2013 - Paris (France)Ipsen and Inspiration Biopharmaceuticals announce closing of the sale of OBI-1 to Baxter International
-
27 February 2013 - Paris (France)Christel Bories joins Ipsen as Deputy Chief Executive Officer
CONTACT US
Didier Véron
Vice-President,
Public Affairs and Corporate Communications
Tel.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58
Send an e-mail
Pipeline
